MMS22L

Across TCGA pan-cancer cohorts, MMS22L mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MMS22L’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where MMS22L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MMS22L is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

LSCC, HNSC, and LUAD are the cancer types where MMS22L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MMS22L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	+0.507	<.001	6	view →
HNSC	Male	III,IV	+0.195	.021	2	view →
LUAD	Female	II,III,IV	−0.903	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

MMS22L–LSCC

Open the LSCC breakdown →